536565
TRIMURTHI
Invest Now
Start SIP in
TRIMURTHI
Performance
- Low
- ₹42
- High
- ₹44
- 52 Week Low
- ₹20
- 52 Week High
- ₹53
- Open Price₹43
- Previous Close₹45
- Volume6,169
Investment Returns
- Over 1 Month + 49.68%
- Over 3 Month + 64.98%
- Over 6 Month + 81.78%
- Over 1 Year + 120.82%
Smart Investing Starts Here Start SIP with Novelix Pharmaceuticals for Steady Growth!
Novelix Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 535.7
- PEG Ratio
- 0.4
- Market Cap Cr
- 57
- P/B Ratio
- 2.8
- Average True Range
- 2.61
- EPS
- -
- Dividend Yield
- 0
- MACD Signal
- 4.84
- RSI
- 60.4
- MFI
- 33.11
Novelix Pharmaceuticals Financials
Novelix Pharmaceuticals Technicals
EMA & SMA
Current Price
₹43.90
-0.81
(-1.81%)

-
- Bearish Moving Average 5
-
- Bullish Moving Average 11
- 20 Day
- ₹42.58
- 50 Day
- ₹35.09
- 100 Day
- ₹28.08
- 200 Day
- ₹21.39
Resistance and Support
43.43
- R3 45.79
- R2 44.85
- R1 44.37
- S1 42.95
- S2 42.01
- S3 41.53
Novelix Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
Date | Purpose | Remarks |
---|---|---|
2025-06-24 | Others | Inter alia, to consider and approve 1. The conversion of Warrants into Equity Shares of the Company. |
2025-05-27 | Audited Results | |
2025-04-12 | Others | Inter-alia, to consider 1. Convening of an EGM for appointment of Non-Executive Independent Director of the Company. 2. To appoint a scrutinizer for the upcoming EGM. 3. Other business matters. |
2025-02-12 | Quarterly Results | |
2024-11-13 | Quarterly Results & Others | Inter-alia, 1. To take note of the Certificate of Whole Time Director & Chief Financial Officer of the Company for the quarter and half year ended 30th September 2024. |
Novelix Pharmaceuticals F&O
About Novelix Pharmaceuticals
- NSE Symbol
- TRIMURTHI
- BSE Symbol
- 536565
- ISIN
- INE314I01036
Similar Stocks to Novelix Pharmaceuticals
Novelix Pharmaceuticals FAQs
Novelix Pharmaceuticals share price is ₹43 As on 23 July, 2025 | 02:15
The Market Cap of Novelix Pharmaceuticals is ₹56.8 Cr As on 23 July, 2025 | 02:15
The P/E ratio of Novelix Pharmaceuticals is 535.7 As on 23 July, 2025 | 02:15
The PB ratio of Novelix Pharmaceuticals is 2.8 As on 23 July, 2025 | 02:15
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.